Overview


Intravitreal (IVT) injectables are sterile pharmaceutical formulations that are administered directly into the vitreous cavity of the eye. This method delivers medication to the retina and the posterior segment of the eye. IVT injectables are commonly used to treat retinal disorders, as they provide high local concentrations of the drug while minimizing systemic exposure.

According to FutureWise analysis, the intravitreal (ivt) injectables market in 2026 is US$18.63 billion and is expected to reach US$29.91 billion by 2036 at a CAGR of 4.85%. The growth in this market is primarily fueled by the rising prevalence of retinal diseases, such as age-related macular degeneration and diabetic retinopathy, especially among the aging global population. 

Growth Drivers

  • Increasing prevalence of retinal disorders like age-related macular degeneration, diabetic retinopathy, and diabetic macular edema.
  • The increasing aging population is making people more susceptible to vision-related diseases.
  • There is a strong adoption of anti-VEGF and biologic therapies as the standard of care.
  • Advances in technology have improved drug-delivery methods, including sustained-release and long-acting formulations.
  • Increasing access to ophthalmology care and enhancing diagnostic capabilities.

Key Trends

  • Shift toward long-acting and extended-duration intravenous (IVT) injectables.
  • Enhancing the development and adoption of biosimilars and affordable therapies.
  • Expansion of intravenous therapy (IVT) treatments to include new retinal and rare eye conditions.
  • Increased investments in research and development (R&D) and strategic collaborations among pharmaceutical companies.
  • The market is experiencing rapid growth in emerging regions, particularly in the Asia-Pacific area.

Market Segmentation and Key Players

The Intravitreal (IVT) Injectables market is segmented by drug class into anti-VEGF agents, corticosteroids, antibiotics, antifungals, and antivirals; by indication into diabetic retinopathy, macular degeneration, retinal vein occlusion, and endophthalmitis; by distribution channel into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies; and by region across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Comprehensive segmentation details are provided in the Segmentation section below.

Leading companies operating in the intravitreal (ivt) injectables market include Alcon, Novartis, Regeneron Pharmaceuticals, AbbVie, Bausch & Lomb, and among others.

Research Methodology

FutureWise Research employs a comprehensive, systematic research methodology that combines primary and secondary research to ensure high accuracy and reliability of data.

Secondary research involves an extensive review of company reports, regulatory databases, scientific journals, paid databases, and industry publications to gain insights into market structure and trends. Primary research consists of in-depth interviews with key opinion leaders, manufacturers, distributors, and healthcare professionals to validate findings.

We utilize both top-down and bottom-up approaches for market sizing and forecasting, supported by data triangulation and expert validation, in order to deliver thorough and actionable insights.

  • Alcon Pharmaceuticals
  • Novartis
  • Regeneron Pharmaceuticals Inc.
  • Allergan
  • Alimera Sciences
  • Bristol Myers Squibb
  • Bausch And Lomb
  • F. Hoffmann-La Roche
  • Thrombogenics
  • Valeant Pharmaceuticals International

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Intravitreal (IVT) Injectables Market: 

Regeneron Pharmaceuticals Inc.

  • Presented compelling real-world outcomes at ARVO 2025 with approximately 40,000 patients, showing longer dosing intervals and sustained visual improvements.
  • The FDA has accepted its supplemental Biologics License Application (sBLA) for expanded indications, specifically for macular edema due to retinal vein occlusion (RVO) and monthly dosing. They have granted priority review, with a decision expected by August 19, 2025.
  • Positive Phase III data from PULSAR/PHOTON and CANDELA confirmed the efficacy and safety of extended dosing (12–16 weeks) in treating wet AMD, DME, and DR.

Alcon Pharmaceuticals

  • Alcon has recently filed patents for innovations in laser-based vitreolysis and SLO-guided floater removal, indicating active development in non-invasive retinal therapies.

Novartis AG

  • Extended-release ocular formulations: Novartis is exploring the application of its expertise in spray-dried particulate formulations—similar to those used in their inhalable Seebri Breezhaler—into intravitreal sustained-release therapies.
  • The company holds key patents in spray-dried lipid-drug powders, reflecting a long-term commitment to controlled-release delivery systems highly relevant to ophthalmology.

Alimera Sciences

  • In May 2023, Alimera completed enrollment of approximately 300 patients in the NEW DAY study, which evaluates ILUVIEN (fluocinolone implant) as a first-line therapy for diabetic macular edema. Data is expected to be released in early 2025.

The global prevalence of retinal diseases such as age-related muscular degeneration, retinal occlusions, and diabetic retinopathy is rising, fuelling the global intravitreal injectables market. Furthermore, the development of anti-vascular endothelial growth factor (anti-VEGF) injections has the potential to extend functional visual acuity in an additional 20% of patients for the rest of their natural lives. Because intravitreal injectables effectively treat retinal problems and are widely used to treat intraocular diseases, the intravitreal injectables market is expected to grow rapidly during the forecast period. There are currently several anti-VEGF drugs on the market, including pegaptanib, ranibizumab, bevacizumab, and aflibercept. Despite the fact that well-designed clinical trials have demonstrated that these agents improve vision in a variety of retinal diseases, each intravitreal injection carries the risk of post-injection and drug-class-related adverse events. The requirement for multiple and long-term injections may increase the risk of ocular and systemic complications. As a result, the post-infections caused by the intravitreal injections are expected to limit the intravitreal injectables market. Favourable regulatory guidelines for designing and manufacturing intravitreal injectables for patient safety will drive market growth. Manufacturers are working to develop intravitreal injectables that meet these regulatory requirements. Furthermore, with a strong pipeline of IVT injections for the treatment of retinal conditions, an increased industry focus on innovation is expected to propel the intravitreal market, providing opportunities for key players in the target market. The use of the disposable device over the conventional method of injectables has increased among individuals due to advantages like less pain score and also a reduction in device cost and manpower. The innovation and development in the device of intravitreal injection are expected to boost the revenue of this target market.

By Drug Class

  • Anti-VEGF
  • Antibiotics
  • Corticosteroids
  • Antifungals
  • Antivirals

By Indication

  • Diabetic Retinopathy
  • Macular Degeneration
  • Endophthalmitis
  • Retinal Vein Occlusions

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Here’s a regional view of where the most progress is happening

Asia-Pacific

  • East Asia is witnessing significant development, especially in countries like China. Key factors driving growth include the increasing prevalence of retinal diseases, such as diabetic retinopathy and age-related macular degeneration (AMD), an aging population, and improved access to healthcare.

North America

  • North America has a significant market share due to its advanced healthcare infrastructure and a high prevalence of retinal disorders. The United States continues to be a leading contributor to the market in the region.

This market research report also emphasizes factors affecting the growth rate in the various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America registered highest share in the market in 2022. The demand for intravitreal (IVT) injectables in North America is predicted to increase as age-related macular degeneration (AMD) becomes more common. Furthermore, due to a favourable reimbursement environment, intravitreal injections are the most frequent ophthalmic operation performed in the nation. This is projected to support market expansion in the coming years. The demand for intravitreal (IVT) injectables in the area is expected to increase because of the ageing population and the burden of retinal illnesses in the region. Besides that, based on drug type; anti-VEGF holds majority share in global market with 91.8% in 2022.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Intravitreal (IVT) Injectables Market By Drug Class, By Indication, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Targeted Antigen launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Intravitreal (IVT) Injectables Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Intravitreal (IVT) Injectables Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Intravitreal (IVT) Injectables Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Intravitreal (IVT) Injectables Market, By Drug Class Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Anti-VEGF
        2. Antibiotics
        3. Corticosteroids
        4. Antifungals
        5. Antivirals

  • 8.   Global Intravitreal (IVT) Injectables Market, By Indication Historical Analysis and Forecast 2026-2036(USD Million)

    •   1. Diabetic Retinopathy
        2. Macular Degeneration
        3. Endophthalmitis
        4. Retinal Vein Occlusions

  • 9.   Global Intravitreal (IVT) Injectables Market, By Distribution Channel Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Drug Stores
        4. Online Pharmacies

  • 10.   North America Intravitreal (IVT) Injectables Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2026-2036

  • 11.   Latin America Intravitreal (IVT) Injectables Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2026-2036

  • 12.   Europe Intravitreal (IVT) Injectables Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2026-2036

  • 13.   Asia Pacific Intravitreal (IVT) Injectables Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2026-2036

  • 14.   Middle East and Africa Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2026-2036

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Targeted Antigens Offered and Financial Layouts)

    •   1. Alcon Pharmaceuticals
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Regeneron Pharmaceuticals Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Allergan
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Alimera Sciences
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bristol Myers Squibb
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bausch And Lomb
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. F. Hoffmann-La Roche
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Thrombogenics
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Valeant Pharmaceuticals International
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

FAQ


The latest trends in Intravitreal (IVT) Injectables Market Research include the development of longer-acting drugs that reduce the frequency of injections, the exploration of combination therapies to improve treatment outcomes, and the use of gene therapy as a potential long-term solution for retinal diseases. Furthermore, there is a growing focus on personalized medicine, aiming to tailor treatments to individual patients based on genetic markers.

Key drivers of the market include:

  • The increasing prevalence of retinal diseases and eye disorders.
  • Technological advancements in drug delivery systems.
  • Growing elderly population more prone to eye diseases.
  • Rising investments in R&D activities by pharmaceutical companies.
  • Enhanced healthcare infrastructure and increased healthcare spending globally.

While the market is growing, there are several challenges, including:

  • High cost of treatment and limited reimbursement policies.
  • Risk of potential side effects and complications associated with IVT injections.
  • Stringent regulatory requirements leading to delays in product approvals.
  • Availability of alternative treatment options.

Technological advancements are significantly impacting the market by improving drug delivery systems, enhancing the efficacy and safety profiles of IVT injectables, and developing sustained-release formulations that reduce the frequency of injections. These innovations are expected to drive further growth in the market.

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 113 519 7222
  • US : +1 347 709 4931

Related Market

Lasik Eye Surgery Devices Market

Read More

Dry Eye Treatment Devices Market

Read More

Diabetic Eye Testing Market

Read More

Dry Eye Medication Market

Read More

Eyesight Test Equipment Market

Read More

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11